Full metadata record
DC FieldValueLanguage
dc.contributor.authorCarlander, Maria-
dc.contributor.authorWirth, Brigitte-
dc.contributor.authorTrottmann, Maria-
dc.contributor.authorCaviglia, Cornelia-
dc.contributor.authorFrei, Christian-
dc.contributor.authorRhomberg, Birgitta-
dc.contributor.authorRohrbasser, Adrian-
dc.contributor.authorEichler, Klaus-
dc.contributor.authorHöglinger, Marc-
dc.date.accessioned2022-07-27T09:17:15Z-
dc.date.available2022-07-27T09:17:15Z-
dc.date.issued2022-
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/25361-
dc.description.abstractObjective: To evaluate the impact of a disease management program (DMP) for patients with diabetes mellitus in a Swiss primary care setting. Methods: In a prospective observational study, we compared diabetes patients in a DMP (intervention group; N=515) with diabetes patients receiving usual care (control group; N=4820) using propensity score matching with entropy balancing. Using a difference-in-difference (DiD) approach we compared changes in outcomes from baseline (2017) to one-year (2017/18), to two-year (2017/19) and to three-year follow-up. Outcomes included four measures for guideline-adherent diabetes care, hospitalization risk, and health care costs. Results: We identified a positive impact of the DMP on the share of patients fulfilling all measures for guideline-adherent care [DiD 2017/18: 7.1%-points, p<0.01; 2017/19: 8.8%-points, p<0.001; 2017/20: 7.3%-points, p<0.01]. The hospitalization risk was lower in the intervention group in all years, but only statistically significant in the one-year follow-up [DiD 2017/18: -5.2%-points, p<0.05; 2017/19: -3.4%-points, not sign.; 2017/20: -4.2%-points, not sign.]. The increase in health care costs was smaller in the intervention than in the control group [DiD 2017/18: CHF -738; 2017/19: CHF -1051, 2017/20: CHF -612], but this effect was not statistically significant. Discussion: The DMP under evaluation seems to exert a positive impact on the quality of diabetes care, reflected in the increase in the measures for guideline-adherent care and in a reduction of the hospitalization risk in the intervention group. It also might reduce health care costs, but only a longer follow-up will show whether the observed effect persists over time.de_CH
dc.language.isoende_CH
dc.rightsLicence according to publishing contractde_CH
dc.subject.ddc362.1041: Gesundheitsökonomiede_CH
dc.subject.ddc616: Innere Medizin und Krankheitende_CH
dc.titleImpact of a diabetes disease management program on guideline-adherent care, hospitalizations and health care costs : a propensity score matching study using real-world datade_CH
dc.typeKonferenz: Sonstigesde_CH
dcterms.typeTextde_CH
zhaw.departementSchool of Management and Lawde_CH
zhaw.organisationalunitWinterthurer Institut für Gesundheitsökonomie (WIG)de_CH
zhaw.conference.details13th European Conference of Health Economics (EuHEA), Oslo, Norway, 5-8 July 2022de_CH
zhaw.funding.euNode_CH
zhaw.originated.zhawYesde_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.publication.reviewKeine Begutachtungde_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen School of Management and Law

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.